exposure of rodents to many different substances, including hypolipidaemic drugs, the phenoxyacetic acid herbicides and industrial chemicals such as phthalates and perfluorofatty acids [ 1-31. Such peroxisome proliferators also cause a number of other changes in rodent liver (see Table  1 ). The capacity of the proliferated peroxisomes to catabolize fatty acids, with concomitant formation of hydrogen peroxide, is dramatically increased. Since at the same time the cellular level of catalase is relatively unchanged, peroxisome proliferation is proposed to result in an increased oxidative stress. Peroxisome proliferators also induce a number of so-called xenobiotic-metabolizing enzymes, including cytochrome P-450 IVA (which is specialized for the omega-and omega-1-hydroxylation of fatty acids) and soluble epoxide hydrolase. Furthermore, long-term treatment of rodents with peroxisome proliferators gives rise to liver tumours.
Research in this area is presently focused on three major questions as discussed below.
( I ) What is the mechanism underlying peroxisome proliferation?
It is generally believed that a heterodimer between a peroxisome proliferator-activated receptor (PPAR) and the retinoic acid receptor (RXR) is involved in RXR and the product of a reporter gene.
In an attempt to test this hypothesis under more in vivo-like conditions, we exposed Morris hepatoma C7800 cells (a cell line originating from Wistar rat liver and known to be responsive to peroxisome proliferators) to arachidonic acid in the absence and presence of all-trans-retinoic acid (which is known to be converted within cells into 9-cis-retinoic acid, the best ligand for RXRs).
Arachidonic acid or all-trans-retinoic acid alone increased acyl-CoA oxidase activity (the rate-limiting step in peroxisomal fatty acid B-oxidation and commonly used to monitor peroxisome proliferation) in the cells by about loo%, while the corresponding increase upon exposure to both of these compounds was about 750%. This synergistic effect supports the involvement of PPAR-RXR heterodimer.
In the same connection, C57/B16 mice were made vitamin A-deficient by supplying pregnant mice with a vitamin A-deficient diet during the last two weeks of pregnancy and feeding the offspring this same diet after weaning. The vitamin A-deticient offspring were utilized for studies at 10-12 weeks of age, at which time the serum level of vitamin A is about 10% of the normal value. After significantly longer periods of vitamin A deficiency, the mice begin to show signs of toxicity.
Vitamin A deficiency itself causes a slight (50-100%) increase in the peroxisomal lauroyl-CoA oxidase, palmitoyl-CoA oxidation and catalase activities in mouse liver. In agreement with this finding, an increased number of peroxisomes were also seen in electron micrographs of vitamin A-deficient hepatocytes. More strikingly, vitamin A deficiency alone caused about a 10-fold increase in the cytosolic level of catalase activity. There was no discernible effect on the level of mitochondrial protein.
When vitamin A-deficient mice were treated with 0.02% perfluoro-octanoic acid (one of the most potent peroxisome proliferators known) in their diet for 10 days, the effects on peroxisomal lauroyl-CoA oxidase, palmitoyl-CoA oxidation and catalase were greatly reduced compared with those obtained upon similar treatment of vitamin A-adequate mice (Table 2 ). On the other hand, the maximal values for cytosolic catalase activity, mitochondrial protein (reflecting a decrease in mitochondrial size) and liver weight (reflecting hepatocyte proliferation) were the same for vitamin A-deficient and
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Environmental Biochemistry Table 2 Effects of vitamin A-deficiency on peroxisome proliferation in mouse liver by perfluoro-octanoic acid -adequate mice. These observations were essentially the same for male and female mice. These findings suggest that the peroxisome proliferation caused by pertluoro-octanoic acid was highly dependent on the vitamin A status of the mouse, whereas other changes invariably associated with peroxisome proliferation in mouse liver may not be as dependent on an adequate level of vitamin A. The ligand which binds to PPAR upon treatment of rodents with peroxisome proliferators is not yet known. One suggestion is that xenobiotic acyl-CoA derivatives bind to PPAR, since the vast majority of peroxisome proliferators contain a carboxylic moiety or another group which can be metabolized to such a moiety in uivo [6, 7] . An alternative hypothesis is that peroxisome proliferators disturb cellular lipid metabolism such that an endogenous ligand for PPAR accumulates. The key to unravelling the mechanism underlying peroxisome proliferation lies in identifying the ligand for PPAR.
There must exist a dietary and/or endogenous peroxisome proliferator(s). The level of this substance may regulate blood fat levels and thereby affect risk for cardiovascular disease. In addition, this substance might possibly be involved in maintaining body temperature and weight.
One candidate for endogenous peroxisome proliferators are naturally occurring fatty acids.
Certain fatty acids are known to activate PPAR [8] and cause peroxisome proliferation in Morris hepatoma C7800 cells [9] . In addition, certain high-fat diets are known to cause moderate levels of peroxisome proliferation [ 10,111.
We have also found that myristic acid (C,.,, saturated) is a potent peroxisome proliferator in Morris hepatoma C7800 cells. Therefore, we fed Wistar rats 5 or 10% myristic acid for lodays and monitored the effects of this treatment. The increase in peroxisomal parameters obtained was small, but clearly significant (Table 3) .
It is our guess that peroxisome proliferation with naturally occurring substances will never be as pronounced as that seen with xenobiotics. Physiological processes must almost always be more tightly regulated in order to maintain homoeostasis.
It seems likely that xenobiotic peroxisome proliferators 'take over' a mechanism designed for endogenous ligands and somehow amplify the effect, perhaps because they cannot be removed as readily by metabolic processes.
Xenobiotic peroxisome proliferators can be used as an extremely valuable experimental tool for studying peroxisome biogenesis and degradation in rodent liver. Exposure to such a substance 'turns on' this biogenesis, whereas termination of this exposure 'turns off biogenesis and accelerates breakdown. Protein targeting and translocation and membrane biogenesis may be investigated.
(2) What is the mechanism by which peroxisome proliferators cause liver cancer?
This mechanism appears to differ from the general pattern of nuclear mutations resulting from the formation of xenobiotic-DNA adducts. Only after long periods of treatment can low levels of such adducts involving peroxisome proliferators be detected in rodent liver using the 32P post-labelling technique One possible explanation for the apparently epigenetic hepatocarcinogenesis caused by peroxisome proliferators is that they cause oxidative stress in the hepatocytes, which may enhance promotion, progression or some other phenomenon involved in the carcinogenic process. In order to test this hypothesis further, we examined the formation of 8-hydroxyguanosine in both nuclear and mitochondrial DNA, as well as the susceptibility of mitochondrial and microsomal membranes to lipid peroxidation after treatment of Sprague-Dawley rats or C57/B16 mice with the peroxisome proliferators perfluoro-octanoic acid (0.02%) or acetylsalicylic acid (1.0%) in the diet for 4,7 or 10 days. After such treatment, the level of 8-hydroxyguanosine in nuclear DNA was somewhat increased, whereas the level of this oxidized base in mitochondrial DNA was decreased. In addition, the susceptibility of mitochondrial and microsomal membranes to ADP-FEZ+-induced lipid peroxidation was decreased, indicating the presence of higher levels of endogenous defences against such oxidative damage after treatment.
These findings indicate that peroxisome proliferation may increase the level of oxidative stress in one compartment of the cell, while decreasing this level in other compartments. Both the presumably increased rate of H202 production by peroxisomes after proliferation, as well as possible secondary cellular responses which lead to [121. increased defences against oxidative stress must be considered in this connection. In recent studies we have seen that the level of H20z in mouse liver is only increased about 25% by treatment with the moderately potent peroxidome proliferator acetylsalicylic acid. At the same time, hepatic levels of ubiquitone and/or vitamin E may be increased by treatment of mice with perfluoro-octanoic acid or acetylsalicylic acid.
Perhaps mutations in mitochondrial DNA or epigenetic processes are involved in the hepatocarcinogenesis brought about in rodents by exposure to peroxisome proliferators. Certainly, this organelle is affected by peroxosime proliferators. We have shown previously that the average mitochondrial size in mouse hepatocytes decreases by about one-third on exposure to potent peroxisome proliferators [ 131. Very recently, we have found that clofibrate, perfluoro-octanoic acid and acetylsalicyclic acid all cause increases in the levels of mRNA species for certain proteins encoded for by the mitochondrial genome.
Finally, another alternative is that peroxisome proliferators may function as promoters, rather than as initiators of hepatocarcinogenesis [ 121.
(3) Does peroxisome proliferation occur in man?
This remains at present a highly controversial question. Some groups report low degrees of peroxisome proliferation in hepatocytes of humans and other primates, whereas others maintain that no proliferation occurs in such cells. Even rodent species other than rats and mice are much less responsive to xenobiotic peroxisome proliferators [ 14,151. It is now known that a protein highly homologous to the rat peroxisome proliferator-activated receptor is expressed in human cells [ 161. Peroxisome proliferation has also been reported to occur in fish, birds, insects and plants. These two observations make it, we believe, highly probable that such proliferation can also occur in man.
Perhaps we have not yet tested an appropriate human system for peroxisome proliferation, since isolated hepatocytes dedifferentiate rapidly. Perhaps the peroxisomes in human hepatocytes are already proliferated, since we eat a diet containing 30-40 caloric percent fat, at least in most parts of the Western world. And finally, perhaps we simply have not yet found an appropriate ligand (or precursor thereof) for the human peroxisome proliferator-activated receptor.
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